Figure 1.
The overall median survival of study group (N = 47) receiving concurrent sorafenib and transarterial treatment was 18.5 months.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.